Doxorubicin-induced behavioral disturbances in rats: Protective effect of melatonin and captopril

Pharmacology Biochemistry and Behavior

Volumn 124, Issue , 2014, Pages 284-289

  Aziriova, S ^a   Repova Bednarova, K ^a   Krajcirovicova, K ^a   Hrenak, J ^a   Rajkovicova, R ^a   Arendasova, K ^a   Kamodyova, N ^a   Celec, P ^a   Zorad, S ^b   Adamcova, M ^c   Paulis, L ^a   Simko, F ^a,b,d  

^a Bratislava   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Center of Excellence NOREG   (Slovakia)

Author keywords

Anxiety; Captopril; Doxorubicin; Melatonin; Oxidative stress; Protection

Indexed keywords

CAPTOPRIL; DOXORUBICIN; MELATONIN; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; EXPLORATORY BEHAVIOR; LIGHT-DARK TEST; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TRANQUILIZING ACTIVITY; TREATMENT DURATION; ANIMAL; ANIMAL BEHAVIOR; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECTS; METABOLISM; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BEHAVIOR, ANIMAL; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAPTOPRIL; DOXORUBICIN; DRUG ANTAGONISM; MALE; MELATONIN; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 84904364404     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.06.021     Document Type: Article

References (47)

1. M.A. Ahmed, H.I. Ahmed, and E.M. El-Morsy Melatonin protects against diazinon-induced neurobehavioral changes in rats Neurochem Res 38 10 2013 2227 2236
2. C.D. Aluise, R. Sultana, J. Tangpong, M. Vore, Clair D. St, and J.A. Moscow et al. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction Adv Exp Med Biol 678 2010 147 156
3. M. Behuliak, R. Palffy, R. Gardlik, J. Hodosy, L. Halcak, and P. Celec Variability of thiobarbituric acid reacting substances in saliva Dis Markers 26 2009 49 53
4. R.F. Deicken Captopril treatment of depression Biol Psychiatry 21 14 1986 1425 1428 (Pubitemid 17191382)
5. S. Duchemin, E. Belanger, R. Wu, G. Ferland, and H. Girouard Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice Physiol Behav 109 2013 63 68
6. O. Erel A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation Clin Biochem 37 2004 277 285 (Pubitemid 38314881)
7. L. Germain, and G. Chouinard Captopril treatment of major depression with serial measurements of blood cortisol concentrations Biol Psychiatry 25 4 1989 489 493 (Pubitemid 19063797)
8. A. Gvozdjakova, F. Simko, J. Kucharska, Z. Braunova, P. Psenek, and J. Kyselovic Captopril increased mitochondrial coenzyme Q10 level, improved respiratory chain function and energy production in the left ventricle in rabbits with smoke mitochondrial cardiomyopathy Biofactors 10 1999 61 65 (Pubitemid 29500621)
9. M.V. Hansen, M.T. Madsen, I. Hageman, L.S. Rasmussen, S. Bokmand, and J. Rosenberg et al. The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial BMJ Open 2 2012 e000647
10. S. Haridas, M. Kumar, and K. Manda Melatonin ameliorates chronic mild stress induced behavioral dysfunctions in mice Physiol Behav 119 2013 201 207
11. J. Hrenak, K. Arendasova, R. Rajkovicova, S. Aziriova, K. Repova, and K. Krajcirovicova et al. Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats Physiol Res 62 Suppl. 1 2013 S181 S189
12. E. Jirkovsky, O. Popelova, P. Krivakova-Stankova, A. Vavrova, M. Hroch, and P. Haskova et al. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways J Pharmacol Exp Ther 343 2012 468 478
13. L. Kaymov, G. Brown, R. Jindla, K. Butto, and C.M. Shapiro A randomized, double blind, placebo-controlled crossover study of the effect of endogenous melatonin on delayed sleep phase syndrome Psychosom Med 63 2001 40 48 (Pubitemid 32125355)
14. I.V. Meira-Lima, A.C. Pereira, G.F. Mota, J.E. Krieger, and H. Vallada Angiotensinogen and angiotensin converting enzyme gene polymorphisms and the risk of bipolar affective disorder in humans Neurosci Lett 293 2 2000 103 106
15. M.J. McKinley, A.L. Albiston, A.M. Allen, M.L. Mathai, C.N. May, and R.M. McAllen et al. The brain renin-angiotensin system: location and physiological roles Int J Biochem Cell Biol 35 6 2003 901 918 (Pubitemid 36379330)
16. F. Liu, J. Havens, Q. Yu, G. Wang, R.L. Davisson, and V.M. Pickel et al. The link between angiotensin II-mediated anxiety and mood disorders with NADPH oxidase-induced oxidative stress Int J Physiol Pathophysiol Pharmacol 4 2012 28 35
17. M.A. Lopes, A. Meisel, U. Dirnagl, F.D. Carvalho, and M.L. Bastos Doxorubicin induces biphasic neurotoxicity to rat neurons Neurotoxicology 29 2 2008 286 293
18. S. Merzoug, M.L. Toumi, N. Boukhris, B. Baudin, and A. Tahraoui Adriamycin-related anxiety-like behavior, brain oxidative stress and myelotoxicity in male Wistar rats Pharmacol Biochem Behav 99 2011 639 647
19. P. Montilla, I. Túnez, M.C. Muñoz, A. López, and J.V. Soria Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration Nephron 76 1997 345 350 (Pubitemid 27296539)
20. G. Munch, R. Keis, A. Wessels, P. Riederer, U. Bahner, and A. Heidland et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA Eur J Clin Chem Clin Biochem 35 1997 669 677
21. E. Oz, and M.N. Ilhan Effects of melatonin in reducing the toxic effects of doxorubicin Mol Cell Biochem 286 1-2 2006 11 15
22. L. Paulis, and F. Simko Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind Physiol Res 56 2007 671 684
23. L. Paulis, O. Pechanova, J. Zicha, S. Liskova, P. Celec, and M. Mullerova et al. Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment J Hypertens 28 Suppl. 1 2010 S19 S24
24. M.I. Phillips, and E.M. de Oliveira Brain renin angiotensin in disease J Mol Med (Berl) 86 6 2008 715 722
25. R.J. Reiter, D.X. Tan, and M.D. Maldonado Melatonin as an antioxidant: physiology versus pharmacology J Pineal Res 39 2005 215 216 (Pubitemid 41140762)
26. R.J. Reiter, D.X. Tan, L.C. Manchester, Terron M. Pilar, L.J. Flores, and S. Koppisepi Medical implications of melatonin: receptor-mediated and receptor independent actions Adv Med Sci 52 2007 11 28
27. K. Repova-Bednarova, S. Aziriova, J. Hrenak, K. Krajcirovicova, M. Adamcova, and L. Paulis et al. Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension Physiol Res 62 Suppl. 1 2013 S135 S141
28. Y.B. Saab, P.R. Gard, M.S. Yeoman, B. Mfarrej, H. El-Moalem, and M.J. Ingram Renin-angiotensin-system gene polymorphisms and depression Prog Neuropsychopharmacol Biol Psychiatry 31 5 2007 1113 1118 (Pubitemid 46810107)
29. L. San, and B. Arranz Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system Eur Psychiatry 23 6 2008 396 402
30. M.C. Schlatter, and L.D. Cameron Emotional suppression tendencies as predictors of symptoms, mood, and coping appraisals during AC chemotherapy for breast cancer treatment Ann Behav Med 40 2010 15 29
31. M. Schepelmann, L. Molcan, H. Uhrova, M. Zeman, and I. Ellinger The presence and localization of melatonin receptors in the rat aorta Cell Mol Neurobiol 31 2011 1257 1265
32. F. Simko, and J. Simko Heart failure and angiotensin converting enzyme inhibition: problems and perspectives Physiol Res 48 1999 1 8 (Pubitemid 29143416)
33. F. Simko, J. Simko, and M. Fabryova ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle Cardiovasc Drugs Ther 17 2003 287 290 (Pubitemid 37421745)
34. F. Simko Chronobiology of blood pressure: emerging implications of melatonin Eur J Clin Invest 42 2012 1252 1254
35. F. Simko, and L. Paulis Melatonin as a potential antihypertensive treatment J Pineal Res 42 2007 319 322 (Pubitemid 46581667)
36. F. Simko, O. Pechanova, V. Pelouch, K. Krajcirovicova, M. Mullerova, and K. Bednarova et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats J Hypertens 27 Suppl. 6 2009 S5 S10
37. F. Simko, O. Pechanova, V. Pelouch, K. Krajcirovicova, P. Celec, and R. Palffy et al. Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril J Hypertens 28 Suppl. 1 2010 S13 S18
38. F. Simko, and O. Pechanova Remodelling of the heart and vessels in experimental hypertension: advances in protection J Hypertens 28 Suppl. 1 2010 S1 S6
39. F. Simko, and L. Paulis Antifibrotic effect of melatonin-perspective protection in hypertensive heart disease Int J Cardiol 168 2013 2876 2877
40. F. Simko, R.J. Reiter, O. Pechanova, and L. Paulis Experimental models of melatonin-deficient hypertension Front Biosci 18 2013 616 625
41. T. Simunek, M. Sterba, O. Popelova, M. Adamcova, R. Hrdina, and V. Gersl Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol Rep 61 2009 154 171
42. V. Srinivasan, S.R. Pandi-Perumal, I. Trakht, D.W. Spence, R. Hardeland, and B. Poeggeler et al. Pathophysiology of depression: role of sleep and the melatonergic system Psychiatry Res 165 3 2009 201 214 [28]
43. V1. Srinivasan, A. Brzezinski, S.R. Pandi-Perumal, D.W. Spence, D.P. Cardinali, and G.M. Brown Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiatry 35 2011 913 923
44. D.X. Tan, L.C. Manchester, M.P. Terron, L.J. Flores, and R.J. Reiter One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 42 2007 28 42 (Pubitemid 44924323)
45. S. Tengattini, R.J. Reiter, D.X. Tan, M.P. Terron, L.F. Rodella, and R. Rezzani Cardiovascular diseases: protective effects of melatonin J Pineal Res 44 2008 16 25 (Pubitemid 350231106)
46. F. Yousaf, E. Seet, L. Venkatraghavan, A. Abrishami, and F. Chung Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: a qualitativesystematic review of randomized trials Anesthesiology 113 4 2010 968 976
47. G.S. Zubenko, and R.A. Nixon Mood-elevating effect of captopril in depressed patients Am J Psychiatry 141 1 1984 110 111 (Pubitemid 14218177)